CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash Flows From Operating Activities:
Net loss	$ (65,153)	$ (42,273)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	86	28
Stock-based compensation expense	3,187	3,258
Accretion of discount/premium on investment securities	28	45
Change in fair value of derivative instruments-warrants	(1,404)	(633)
Changes in operating assets and liabilities:
Security deposit	(69)
Accounts payable and accrued expenses	3,086	4,575
Prepaid expenses and other current assets	(394)	(3,697)
Total Adjustments	4,520	3,576
Net Cash Used in Operating Activities	(60,633)	(38,697)
Cash Flows From Investing Activities:
Loans to related parties		(270)
Net proceeds / (purchases) of available-for-sale securities	30,000	(50,000)
Additions to property and equipment	(104)	(615)
Repayment on ContraVir loan receivable	455
Net Cash Provided by /(Used in) Investing Activities	30,351	(50,885)
Cash Flows From Financing Activities:
Issuance of common stock pursuant to controlled equity sales agreement	25,612	94,734
Issuance of common stock of ContraVir	3,224
Fees and expenses related to equity issuances	(721)	(5,623)
Proceeds from exercise of stock options	36	119
Distribution of cash associated with ContraVir Spinoff	(3,230)
Net Cash Provided by Financing Activities	24,921	89,230
Net decrease in cash and cash equivalents	(5,361)	(352)
Cash and cash equivalents at beginning of period	18,130	12,416
Cash and cash equivalents at end of period	12,769	12,064
Supplementary disclosure of cash flow information:
Cash paid for taxes	55	37
Supplementary disclosure of non-cash investing and financing activities:
Value of warrants classified as derivative liability-net		(3,575)
Recapitalization of Synergy		4,904
Distribution of net assets of ContraVir	$ 84